Search

Displaying results 4011 - 4020 of 10000 in total
  1. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use. … Vanoxerine is a highly selective dopamine transporter antagonist. It was synthesized in the late 1970s and developed as a potential treatment for depression.

  2. Drug

    Apramycin

    go.drugbank.com/drugs/DB04626
    InvestigationalVet approved

    Apramycin is a structurally unique antibiotic that contains a bicyclic sugar moiety and a monosubstituted deoxystreptamine. It is not approved for use in humans. … Apramycin is an aminoglycoside antibiotic and has a bactericidal action against many gram-negative bacteria.

    Synonyms: Nebramycin II, 4-O-((8R)-2-amino-8-O-(4-amino-4-deoxy-α-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-D-glycero-α-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl)-2-deoxy-D-streptamine
  3. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. … Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Trichophyton mentagrophytes

    go.drugbank.com/drugs/DB10446
    Approved

    Trichophyton mentagrophytes is a fungus which can provoke allergic reactions. Trichophyton mentagrophytes extract is used in allergenic testing.

    Mixtures: Trichophyton for Intradermal Skin TestingCategories: Non-Standardized Fungal Allergenic Extract
  5. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. … Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB16901
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  7. Drug

    Influenza B virus B/Austria/1359417/2021 BVR-26 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16904
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16916
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16918
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated